AstraZeneca

AZNleader

AstraZeneca is a global biopharmaceutical company with a market-leading oncology portfolio and strong positions in cardiovascular, respiratory, and rare disease therapies.

⇄ Compare

Produk & Pendapatan

Pangsa Pendapatan Produk

Komposisi Pendapatan ($49.8B)

Data statis (memuat keuangan langsung…)

Oncology (40%)

BioPharmaceuticals (38%)

Rare Disease (Alexion) (17%)

Other (5%)

Komposisi segmen dan pelanggan utama

Detail produk

Oncology Portfolio40%

Tagrisso, Imfinzi, Enhertu, and Lynparza cancer treatments

Cardiovascular/Renal/Metabolic22%

Farxiga, Brilinta, and Lokelma for heart and kidney disease

Respiratory & Immunology20%

Symbicort, Fasenra, and Tezspire for asthma and COPD

Rare Disease (Alexion)18%

Soliris, Ultomiris for complement-mediated diseases

Hubungan Rantai Pasok

Pesaing

Merck & Co.

Oncology immunotherapy

Dampak: High — PD-L1 vs PD-1 competition

Pfizer Inc.

Respiratory and oncology

Dampak: Medium — multiple overlapping areas

Mitra

Eli Lilly and Company

Enhertu co-development (with Daiichi Sankyo)

Dampak: N/A — Daiichi partner, Lilly rival

Konteks makro dan pasar

제약 / 바이오Berita sektor

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Katalis mendatang

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Berita terkini

Memuat berita...

Analisis AI

Klik "Dapatkan Analisis AI" untuk analisis rantai pasok AstraZeneca.

Info Perusahaan

Kantor Pusat

Cambridge, United Kingdom

Didirikan

1999

Karyawan

89,000+

Situs Web

astrazeneca.com

Gambaran umum sektor — 제약 / 바이오

Berita sektor